Your Health, We Care
Release date: 2026-03-27 16:15:57 Recommended: 3
Anagrelide, as a platelet-reducing medication, plays an important role in the treatment of specific hematologic disorders. Clinical application requires strict adherence to its indications, contraindications, and key considerations for special populations.
(1) AGRYLIN (anagrelide) is a platelet-reducing agent indicated for the treatment of thrombocytosis secondary to myeloproliferative neoplasms to reduce elevated platelet counts and the risk of thrombosis, and to improve associated symptoms, including thrombohemorrhagic events.
(2) This medication is specifically used for thrombocytosis resulting from myeloproliferative neoplasms. The primary goal is to maintain platelet levels within a safe range, thereby reducing the incidence of thrombosis-related complications.
Use should be avoided in patients with known risk factors for QT interval prolongation, including congenital long QT syndrome, known history of acquired QTc prolongation, medications that can prolong the QTc interval, and patients with hypokalemia.
(1) Coadministration with drugs known to prolong the QT interval is prohibited, including but not limited to chloroquine, clarithromycin, haloperidol, methadone, moxifloxacin, amiodarone, disopyramide, procainamide, and pimozide.
(2) As anagrelide is a phosphodiesterase 3 (PDE3) inhibitor, concomitant use of medications with similar properties, such as positive inotropes and other PDE3 inhibitors (e.g., cilostazol, milrinone), should be avoided.
(3) Aspirin and drugs that increase bleeding risk should also be used with caution. Concomitant use of AGRYLIN and aspirin increases the risk of major bleeding events, particularly in patients also receiving other medications known to cause bleeding.
(1) Anagrelide and its active metabolite are primarily metabolized by CYP1A2.
(2) Drugs that inhibit CYP1A2 (e.g., fluvoxamine, ciprofloxacin) may increase anagrelide exposure.
(3) Patients concomitantly taking CYP1A2 inducers may require dosage adjustment to compensate for reduced anagrelide exposure.
(1) Patients with moderate hepatic impairment should initiate treatment at 0.5 mg per day, with frequent monitoring for cardiovascular events.
(2) Hepatic impairment increases anagrelide exposure and may increase the risk of QTc prolongation.
(3) Use of anagrelide should be avoided in patients with severe hepatic impairment.
The safety and effectiveness of AGRYLIN have been established in pediatric patients aged 7 years and older. No data are available for pediatric patients under 7 years of age.
No overall differences in safety or effectiveness have been observed between these subjects and younger subjects, but greater sensitivity in some older individuals cannot be ruled out.
(1) Available case report data on anagrelide use in pregnant women have not identified a drug-related risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.
(2) Lactation: No information is available regarding the presence of anagrelide in human milk, its effects on breastfed children, or its impact on milk production.
(3) Due to the potential risk of serious adverse reactions, patients are advised not to breastfeed during treatment with AGRYLIN and for one week after the final dose.
